Compare Sana Biotechnology Inc (SANA) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Simon Property Group Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Simon Property Group Inc trades at $199.42 (market cap $64.59B). The key difference: Simon Property Group Inc is far larger — about 77.2× Sana Biotechnology Inc's market cap, and Simon Property Group Inc pays a 4.46% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Simon Property Group Inc for 99 Days on average.
| SANA | SPG | |
|---|---|---|
Market Cap | $836.71M | $64.59B |
Volume | 4,507,444 | 1,093,907 |
Sector | Health | Real Estate |
52-Week High | $5.92 | $236.70 |
52-Week Low | $2.68 | $173.35 |
Typical Hold Time | 23 Days | 99 Days |
Enterprise Value | $749.96M | $93.03B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Simon Property Group (SPG) trades at $199.61, up 1.02% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results, including revenue of $6.36B and net income of $4.63B, with a net margin of 72.7%. Recent news highlights leasing demand strength and a new media network launch, while analysts maintain a consensus price target of $222.90.
SPG offers value with a P/E of 14.09 and robust profitability, but faces risks from high debt levels and interest rate sensitivity. The stock's upside potential hinges on sustained retail demand and effective debt management, with institutional sentiment leaning neutral amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
